Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
MEI Pharma, Inc.
Beth Israel Deaconess Medical Center
Eli Lilly and Company
Prelude Therapeutics